Lv4
665 积分 2021-09-04 加入
Validation of the Dyadic Coping Inventory with Chinese couples: Factorial structure, measurement invariance, and construct validity
2天前
已完结
Assessment of end‐of‐treatment transition needs for pediatric cancer and hematopoietic stem cell transplant patients and their families
1个月前
已完结
Screening and comorbidity of clinical levels of fear of cancer recurrence
2个月前
已完结
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
2个月前
已完结
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
2个月前
已完结
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
2个月前
已完结
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
2个月前
已完结
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
2个月前
已完结
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
2个月前
已完结
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
2个月前
已关闭
皖公网安备34019202002308
